Mammographic screening in women aged 40–49 years was associated with a significant decrease in breast cancer mortality, and the findings suggest potential benefits and support consideration of screening expansion to this population.
Abstract
Introduction: Breast cancer is the most prevalent malignancy among women and a leading cause of cancer-related mortality. While mammographic screening is well established for women aged 50 years and older, its implementation for those aged 40–49 years remains controversial.
Objective: This systematic review assesses the positive and negative impacts associated with expanding screening to this population: mortality reduction, radiation exposure, diagnostic difficulty, and associated costs.
Methods: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and the PICO framework: women aged 40–49 years (population); mammography screening (intervention); absence of mammographic screening or usual care (comparison); and breast cancer mortality, mortality rate, and survival (outcomes). PubMed/MEDLINE databases were searched for studies published since 2020, using the terms “breast cancer”, “mammography” and “40–49 years”. Inclusion criteria covered observational studies, clinical trials, and comparative studies, and studies were independently assessed by two reviewers. Data extraction was performed by six reviewers using standardized forms. Due to methodological heterogeneity, results were synthesized narratively.
Results: Of the 34 studies identified, five met the research goals and inclusion criteria: three randomized controlled trials and two observational studies. Screening was associated with a reduction in breast cancer mortality, with one trial reporting a relative risk (RR) of 0.75 (95% confidence interval: 0.58–0.97) at ten years, and one included meta-analysis showing approximately 18% reduction (RR=0.82) in women aged 39–49 years. However, higher rates of false-positive results and interval cancers, and lower sensitivity were observed with mammographic screening in this age group. Additional concerns included overdiagnosis and increased psychological and economic burden.
Conclusion: Mammographic screening in women aged 40–49 years was associated with a significant decrease in breast cancer mortality. Despite limitations related to overdiagnosis, reduced sensitivity, increased false positives, and radiation exposure, the findings suggest potential benefits and support consideration of screening expansion to this population. Nevertheless, further analyses are pivotal to better evaluate long-term clinical and socioeconomic impacts.
Abstract Background Breast cancer is the leading cause of cancer death among women globally. In Italy, approximately 55,900 new cases and 15,500 deaths were recorded in 2022–2023. In Sicily, mammographic screening (MS) adherence persistently falls below national and European targets, creating a health equity gap. In de...
M. LaBella, S. Scondotto, W. P. Addario et al.· European Journal of Public H...· 0 citations
The need for strategies to improve smoking history documentation and promote tobacco cessation efforts in cancer screening programs is highlighted and the Pink & Pearl program, a co-located breast and lung cancer screening initiative at these sites, will be evaluated.
B. Odeny, Sri Gopalsamy Ramaswamy, Benjamin Bowe et al.· Research Square· 0 citations
The increase in mortality associated with reduced screening coverage suggests low adherence to early detection and possible inefficiencies in local public health policies.
Antonio Railman Oliveira Gouvêa· Mastology· 0 citations
AgeX will reliably assess the clinical- and cost-effectiveness of extending breast screening to younger and/or older women, and will inform future screening policy in the UK and in countries with similar screening programmes.
A. Babiker, S. MacMahon, A. Halliday et al.· Trials· 0 citations
Background: Age based mammography screening has served as the foundation of breast cancer (BC) detection programmes, demonstrating significant reduction in BC mortality. However, reliance on age alone fails to account for individual risk variation, which contributes to overdiagnosis, false positives and interval cancer...
Cancer Society, Akshaya Indrakumar, T. Abdelsamad et al.· UCC Student Medical Journal· 0 citations
It is suggested that among older survivors of breast cancer, continued surveillance mammography was not associated with a reduced risk of advanced second primary breast cancer, and surveillance decisions should be individualized given the potential burdens of continued surveillance.
Ilana B. Richman, Jessica B. Long, Meghan E. Lindsay et al.· JAMA Internal Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.